On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.
What Happened
William Blair analysts described this as a “once-in-a-blue-moon” miss for Lilly’s otherwise dominant obesity franchise. They highlighted that orforglipron’s 9.1% placebo-adjusted weight loss at the 36 mg dose underperformed compared to weekly subcutaneous Wegovy, which delivers 12–13% weight loss.
Also Read: Trump Administration Plan Signals Shift Toward Weight-Loss Drug Coverage For Medicare Patients
Additionally, gastrointestinal side effects were comparable to Wegovy, but orforglipron had a higher treatment discontinuation rate (5.1–10.3% vs. 7.0% for Wegovy, 2.6% for placebo).
They also noted early plateauing of weight loss and persistent side effects as potential liabilities for orforglipron, as previously flagged during the ACHIEVE-1 presentation at the American Diabetes Association.
This rare underperformance opens the door for smaller biopharma competitors, analyst Andy Hsieh of William Blair noted.
“From a stock perspective, we believe that Eli Lilly’s rare miss from its otherwise impenetrable obesity franchise could create an opening for smaller competitors,” he added.
Novo Nordisk
Viking Therapeutics
Viking is expected to report Phase 2 VENTURE-Oral results of the oral tablet formulation of VK2735 in obesity in the second half of 2025. Analyst Hsieh expects the data readout could be as early as later this month.
Results from a 28-day Phase 1 multiple ascending dose trial of VK2735 in healthy volunteers with a BMI ≥30 demonstrated dose-dependent reductions in mean body weight from baseline, ranging up to 8.2%.
Persistent weight loss effects were observed at follow-up visits through Day 57, ranging up to 8.3% from baseline, four weeks after the last dose of VK2735 was administered.
Structure Therapeutics
Structure Therapeutics, which is advancing the oral small molecule aleniglipron that resembles orforglipron but with a shorter half-life, is expected to report results from two Phase 2 studies, ACCESS and ACCESS II, in the fourth quarter.
Structure Therapeutics is also conducting three new aleniglipron clinical studies as planned, which will generate additional data to competitively position aleniglipron and further support the design of the Phase 3 program.
In June 2024, Structure Therapeutics unveiled 12-week topline obesity data from its Phase 2a study of GSBR-1290.
In the Phase 2a obesity study, GSBR-1290 demonstrated a clinically meaningful and statistically significant placebo-adjusted mean decrease in weight of 6.2% at 12 weeks.
Tern Pharmaceuticals
Tern is developing TERN-601, an oral glucagon-like peptide-1 receptor agonist (GLP1-RA) for obesity. The Phase 2 FALCON trial enrollment completed in the second quarter of 2025 and topline 12-week data is expected in the early fourth quarter of 2025.
Price Action: VKTX stock is up 11.2% at $35.46, TERN stock is up 3.70% at $5.88, NVO stock is up 7.47% at $48.79, and GPCR stock is up 7.36% at $17.58 at last check Thursday.
Read Next:
Photo by shisu_ka via Shutterstock
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
